Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases
Morquio 一种将基因转移与凝集素增强酶递送相结合的疗法,用于治疗罕见代谢性儿童疾病的多系统临床损伤
基本信息
- 批准号:10821924
- 负责人:
- 金额:$ 29.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-20 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcetylgalactosamineAddressAffectAntibodiesBehavioralBenchmarkingBindingBiodistributionBiological ModelsCardiacCardiovascular systemCaregiversCartilageCellsCentral Nervous SystemCessation of lifeChildChildhoodChondrocytesChondroitin SulfatesClinicClinicalConnective TissueDataDepositionDevelopmentDiseaseDoseEffectivenessEnzymesEpiphysial cartilageExhibitsFamilyGalactosamineGalactoseGene TransferGenesGeneticGenetic DiseasesGoalsHalf-LifeHealth systemHeartHeart ValvesHumanHuman GeneticsImmuneImmune SeraImmune responseImpairmentInfusion proceduresKeratan SulfateKidneyLeadLectinLengthLigamentsLiverLungLysosomal Storage DiseasesLysosomesMammalian CellMediatingMedicalMetabolicMucopolysaccharidosesMucopolysaccharidosis IMucopolysaccharidosis IV AMusMusculoskeletalOrganPathologicPathologyPatientsPharmaceutical PreparationsPhasePlant LectinsProgressive DiseaseProtein SecretionPublic HealthQuality of lifeRecombinantsResearchRespiration DisordersSerumSiteSkeletal MuscleSmall Business Innovation Research GrantSpecificitySulfatasesSulfateTechnologyTestingTherapeutic EffectTimeTissuesToxicologyTracheaTransfectionTranslatingbonecostdesigndrug efficacyenzyme activityenzyme replacement therapygene therapyglucosaminoglycansimmunogenicityimprovedin vitro testingineffective therapieslead candidatemanufacturemouse modelpre-clinicalpreclinical studypromoterpublic health relevancerare genetic disorderrespiratoryskeletaltransgene expressiontreatment strategyuptake
项目摘要
Mucopolysaccharidosis Type IVA (MPS-IVA; also called Morquio A Syndrome) is a rare genetic childhood
disorder characterized by multi-systemic pathologies affecting the respiratory, cardiovascular, musculoskeletal,
and central nervous systems leading to devastating quality-of-life and early death. The disease is due to
deficiencies in N-acetylgalactosamine-6-sulfate sulfatase (GALNS) causing progressive and pathological
accumulation of the glucosaminoglycans (GAGs) keratan sulfate and chondroitin sulfate in multiple organs and
tissues. The impact of keratan/chondroitin sulfate accumulation on bone, cartilage, and connective tissues is
particularly striking, leading to debilitating cardiac, respiratory, and skeletal pathologies. An enzyme replacement
therapy (ERT) comprising recombinant human GALNS is currently available but shows no improvement of these
pathologies. Immunogenicity involving the development of neutralizing anti-drug antibodies is also an issue with
this ERT. BioStrategies LC has developed an enzyme delivery technology based on the plant lectin RTB which
greatly enhances delivery of fused enzymes to hard-to-treat cells and tissues including musculoskeletal, cardiac,
respiratory and central nervous systems – sites that have been particularly recalcitrant to effective delivery of
corrective doses of replacement enzymes. Previous studies using murine MPS I as a model system
demonstrated that weekly treatment with enzyme-RTB fusions showed normalization of key bone structural
parameters, CNS substrate accumulation, and behavioral benchmarks of the disease. Additionally, the RTB
carrier successfully mitigated any issues associated with anti-drug immunogenicity. Thus, RTB-mediated
delivery may address the key limitation of current Morquio ERTs to treat the debilitating multisystemic
pathologies of this disease.
Our goal in this SBIR is to develop a ”delivery-enhanced” gene therapy drug comprising an RTB:GALNS
fusion and to perform key preclinical studies. The specific aims of this Phase I SBIR are to 1) Develop and
optimize an RTB:GALNS construct for optimal expression and secretion that retain enzymatic activity and lectin
binding capacity; 2) Determine long-term transgene expression and serum stability by assessing different
promoters; and 3) Evaluate biodistribution of the enzyme and substrate reduction in difficult-to-treat tissues in
the Morquio A mouse model. Our objective is to translate these breakthroughs to produce a “delivery-enhanced”
MPS IVA therapy that will effectively treat disease manifestations that remain a significant unmet medical need
for these patients. The proof of concept generated in these studies will provide the basis to design IND enabling
studies in a Phase II that include GMP manufacture plans, tox studies, and regulatory IND submissions.
IVA型粘多糖样变性(MPS-IVA;也称为Morquio A综合征)是一种罕见的遗传性儿童病
以影响呼吸、心血管、肌肉骨骼
和中枢神经系统,导致毁灭性的生活质量和过早死亡。这种疾病是由于
N-乙酰半乳糖胺-6-硫酸酯硫酸酯酶(GALNS)缺乏导致进行性和病理性
葡糖胺聚糖(GAG)、硫酸角质素和硫酸软骨素在多个器官中蓄积,
组织中角蛋白/硫酸软骨素积累对骨、软骨和结缔组织的影响是
特别引人注目的是,导致使人衰弱的心脏、呼吸系统和骨骼病变。酶替代
包含重组人GALNS的ERT治疗(ERT)目前是可获得的,但没有显示出这些改善。
病理学涉及中和抗药抗体的发展的免疫原性也是免疫治疗的一个问题。
这个ERT。BioStrategies LC开发了一种基于植物凝集素RTB的酶递送技术,
极大地增强了融合酶向难以治疗的细胞和组织的递送,包括肌肉骨骼,心脏,
呼吸系统和中枢神经系统-特别难以有效提供
补充酶的正确剂量先前使用鼠MPS I作为模型系统的研究
结果表明,每周一次的酶-RTB融合治疗显示关键骨结构正常化,
参数、CNS底物积累和疾病的行为基准。此外,RTB
载体成功地减轻了与抗药物免疫原性相关的任何问题。因此,RTB介导
递送可以解决当前Morquio Erts治疗衰弱的多系统性
这种疾病的病理。
我们在该SBIR中的目标是开发包含RTB:GALNS的“递送增强的”基因治疗药物。
融合并进行关键的临床前研究。第一阶段SBIR的具体目标是:1)开发和
优化RTB:GALNS构建体以获得最佳表达和分泌,其保留酶活性和凝集素
2)通过评估不同的转基因结合能力来确定长期转基因表达和血清稳定性;
启动子;和3)评估酶的生物分布和底物在难处理组织中的减少,
Morquio A小鼠模型。我们的目标是将这些突破转化为“交付增强型”
MPS IVA治疗将有效治疗仍然是一个显著未满足的医疗需求的疾病表现
对于这些患者。这些研究中产生的概念验证将为设计IND提供基础,
II期研究,包括GMP生产计划、毒性研究和监管IND提交。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Walter Acosta其他文献
Walter Acosta的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Walter Acosta', 18)}}的其他基金
Krabbe disease therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat pathologies of the CNS
克拉伯病疗法将基因转移与凝集素增强酶递送相结合,以治疗中枢神经系统疾病
- 批准号:
10547167 - 财政年份:2022
- 资助金额:
$ 29.59万 - 项目类别:
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery
通过凝集素介导的递送提高 MPS I ERT 功效
- 批准号:
9346992 - 财政年份:2017
- 资助金额:
$ 29.59万 - 项目类别:
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization
罕见儿童遗传病的酶替代疗法:减轻免疫敏化的 ERT 递送系统
- 批准号:
9048190 - 财政年份:2016
- 资助金额:
$ 29.59万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 29.59万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 29.59万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 29.59万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 29.59万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 29.59万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 29.59万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 29.59万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 29.59万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 29.59万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 29.59万 - 项目类别:
Research Grant